Latest Expert Opinions

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
March 29, 2018

19% yield. The street expects a cut here. Change in the media business is affecting them as an old-time media business. They look cheap now. Hasn’t done a lot of work on this name. There is risk here.

Show full opinionHide full opinion

19% yield. The street expects a cut here. Change in the media business is affecting them as an old-time media business. They look cheap now. Hasn’t done a lot of work on this name. There is risk here.

COMMENT
COMMENT
March 29, 2018

What company do you prefer CN Rail (CNR-T) or TransCanada (TRP-T)? He likes both. Near term he likes a little more Transcanada (TRP-T) as it is an asset class that is in shortage now. CN Rail (CNR-T) took the cost cutting a little too far and is struggling a little but long term they are a great business.

Show full opinionHide full opinion

What company do you prefer CN Rail (CNR-T) or TransCanada (TRP-T)? He likes both. Near term he likes a little more Transcanada (TRP-T) as it is an asset class that is in shortage now. CN Rail (CNR-T) took the cost cutting a little too far and is struggling a little but long term they are a great business.

Alex Ruus

Unlock Ratings

Price
$94.160
Owned
Unknown
COMMENT
COMMENT
March 29, 2018

What company do you prefer CN Rail (CNR-T) or TransCanada (TRP-T)? He likes both. Near term he likes a little more Transcanada (TRP-T) as it is an asset class that is in shortage now. CN Rail (CNR-T) took the cost cutting a little too far and is struggling a little but long term they are a great business.

Show full opinionHide full opinion
TC Energy (TRP-T)
March 29, 2018

What company do you prefer CN Rail (CNR-T) or TransCanada (TRP-T)? He likes both. Near term he likes a little more Transcanada (TRP-T) as it is an asset class that is in shortage now. CN Rail (CNR-T) took the cost cutting a little too far and is struggling a little but long term they are a great business.

Alex Ruus

Unlock Ratings

Price
$53.280
Owned
Unknown
TOP PICK
TOP PICK
March 29, 2018

Large cap that is the number two health insurer in the US. Long-term holding in the fund. Growth strongly. One of the solutions to rising health-care costs. Trades at 14 times next year earnings. (Analysts’ price target is $274.63)

Show full opinionHide full opinion
Anthem Inc (ANTM-N)
March 29, 2018

Large cap that is the number two health insurer in the US. Long-term holding in the fund. Growth strongly. One of the solutions to rising health-care costs. Trades at 14 times next year earnings. (Analysts’ price target is $274.63)

TOP PICK
TOP PICK
March 29, 2018

Providing power in Central America. They are bringing down the price of power in Nicaragua. Management is doing an outstanding job. 17% cash flow yield so lots of upside here. Dividend Yield if 4.2% (Analysts’ price target is $26.00)

Show full opinionHide full opinion

Providing power in Central America. They are bringing down the price of power in Nicaragua. Management is doing an outstanding job. 17% cash flow yield so lots of upside here. Dividend Yield if 4.2% (Analysts’ price target is $26.00)

TOP PICK
TOP PICK
March 29, 2018

A company with no revenue now. Drug developer. They are into phase 3 trials. A $33 million market cap company with half that in cash in their balance sheet. Probably going to be taken out by a large pharma once the drug is approved. (Analysts’ price target is $5.21)

Show full opinionHide full opinion
Acasti Pharma (ACST-X)
March 29, 2018

A company with no revenue now. Drug developer. They are into phase 3 trials. A $33 million market cap company with half that in cash in their balance sheet. Probably going to be taken out by a large pharma once the drug is approved. (Analysts’ price target is $5.21)